Cardiovascular Diseases


Late Endovascular Thrombectomy Effective in Vertebrobasilar Artery Occlusion

A multicenter, prospective Chinese cohort study suggested that endovascular thrombectomy (EVT) plus best medical treatment (BMT) improved functional outcomes and survival in patients with vertebrobasilar artery occlusion treated beyond 24 hours after last known well time. Conducted between 2019 and 2024 across 11 comprehensive stroke centers in China, the study […]


Low Sodium DASH Diet Reduced BP

A US randomized, 4-period crossover feeding study revealed that sodium reduction, especially when combined with a Dietary Approaches to Stop Hypertension (DASH)-style diet optimized for diabetes (DASH4D), can significantly lower blood pressure (BP) in patients with type 2 diabetes (T2D) and high BP, even among those already using multiple antihypertensive […]


Global Study of Stroke Risk Factors

A study revealed that stroke remains a major global health challenge, influenced by numerous risk factors that vary across regions and populations. The study analyzed stroke-related mortality from 1990 to 2021 using Global Burden of Disease 2021 data, focusing on three primary stroke subtypes: ischemic stroke, intracerebral hemorrhage, and subarachnoid […]


Geographical Variation in Lipoprotein (a) Levels Among CHD Patients

A global study suggested that most patients with coronary heart disease (CHD) have Lipoprotein (a) [Lp(a)] levels below risk-enhancing thresholds with wide geographical variations. The study assessed Lp(a) levels in 3,928 CHD patients across 13 countries in six World Health Organization regions. Median Lp(a) level was 32 nmol/L, with 17.6% […]


Obicetrapib Effective and Safe in Improving Lipids

Two randomized, controlled trials evaluated the efficacy and safety of obicetrapib, an oral cholesteryl ester transfer protein (CETP) inhibitor, in lowering low-density lipoprotein (LDL) cholesterol in patients at high risk for atherosclerotic cardiovascular disease (ASCVD). Both trials show that obicetrapib is effective in reducing LDL cholesterol, with enhanced efficacy when […]


Dose Response of Physical Activity in CVD and Mortality

Two recent studies highlight the importance of physical activity volume and intensity in reducing cardiovascular disease (CVD) risk and improving longevity. The first study analyzed data from over 24,000 middle-aged and older non-exercisers in the UK Biobank, examining the effects of incidental physical activity (IPA)—unstructured daily movement outside formal exercise—on […]


Faster Walking Pace May Reduce Risk of Cardiac Arrhythmias

A prospective UK cohort study found that both self-reported average or brisk walking pace and accelerometer-measured time spent walking at moderate or brisk pace were associated with a lower risk of cardiac arrhythmias. These associations were partially mediated by metabolic and inflammatory factors. Self-reported walking pace data were available for […]


Comparative CVD Efficacy of Newer Glucose-Lowering Drugs in Elderly T2D Patients

A Danish nationwide cohort study provided real world evidence that both glucagon-like peptide 1 receptor agonists (GLP1-RAs) and sodium-glucose cotransporter 2 inhibitors (SGLT-2is) were associated with reduced rates of 3-point major adverse cardiovascular events (3P-MACE) and hospitalization for heart failure (HHF) compared to dipeptidyl peptidase 4 inhibitors (DPP-4is). Compared to […]